argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-113, ARGX-110, ARGX-115, ARGX-112 etc. The company operates in Netherlands, Germany, Denmark, Belgium, Switzerland, United States and Luxembourg. It derives the majority of its revenues from Switzerland.
| Website: | www.argenx.com |
| Email: | info@argenx.com |
| Main Phone: | +31 763030488 |
| Address: | Willemstraat 5 |
| City / Town: | Breda |
| Country: | NLD |
| Postal Code: | 4811 |
| Exchange: | GREY |
| CEO: | Tim Van Hauwermeiren |
| Employees: | 73 |
| Last Price 74.29 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close 74.29 |
| Last Trade | Volume 0 | 52 Wk Hi 85.00 | 52 Wk Low 51.75 |
| Market Cap 2.7 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 35,928,544.00 | EPS (TTM) -1.66 | PE Ratio N/A | Exchange Greys |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
